Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Declines By 18.8%

Cocrystal Pharma, Inc. (NASDAQ:COCP) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 214,196 shares, a decline of 18.8% from the February 26th total of 263,840 shares. Currently, 2.2% of the company’s shares are sold short. Based on an average daily trading volume, of 34,698 shares, the days-to-cover ratio is currently 6.2 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $6.00.

Cocrystal Pharma Price Performance

Cocrystal Pharma stock remained flat at $1.03 during midday trading on Monday. The company had a trading volume of 1,822 shares, compared to its average volume of 63,307. The stock has a market capitalization of $14.20 million, a PE ratio of -1.10 and a beta of 1.18. The firm has a fifty day moving average price of $1.02 and a 200-day moving average price of $1.07. Cocrystal Pharma has a 52-week low of $0.86 and a 52-week high of $2.67.

Insider Activity at Cocrystal Pharma

In related news, Director Phillip Md Et Al Frost acquired 50,000 shares of the company’s stock in a transaction dated Friday, February 6th. The stock was bought at an average price of $0.95 per share, with a total value of $47,500.00. Following the purchase, the director directly owned 1,888,551 shares in the company, valued at $1,794,123.45. The trade was a 2.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have bought 120,000 shares of company stock worth $114,400. Corporate insiders own 28.14% of the company’s stock.

Institutional Trading of Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC purchased a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. 6.72% of the stock is owned by hedge funds and other institutional investors.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.